Literature DB >> 28628040

Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity.

Deqiang Zhang1, Xin Tong1, Kyle VanDommelen1, Neil Gupta1, Kenneth Stamper1, Graham F Brady1, Zhuoxian Meng2,3, Jiandie Lin3, Liangyou Rui1, M Bishr Omary1, Lei Yin1.   

Abstract

Epidemiologic and animal studies implicate overconsumption of fructose in the development of nonalcoholic fatty liver disease, but the molecular mechanisms underlying fructose-induced chronic liver diseases remain largely unknown. Here, we have presented evidence supporting the essential function of the lipogenic transcription factor carbohydrate response element-binding protein (ChREBP) in mediating adaptive responses to fructose and protecting against fructose-induced hepatotoxicity. In WT mice, a high-fructose diet (HFrD) activated hepatic lipogenesis in a ChREBP-dependent manner; however, in Chrebp-KO mice, a HFrD induced steatohepatitis. In Chrebp-KO mouse livers, a HFrD reduced levels of molecular chaperones and activated the C/EBP homologous protein-dependent (CHOP-dependent) unfolded protein response, whereas administration of a chemical chaperone or Chop shRNA rescued liver injury. Elevated expression levels of cholesterol biosynthesis genes in HFrD-fed Chrebp-KO livers were paralleled by an increased nuclear abundance of sterol regulatory element-binding protein 2 (SREBP2). Atorvastatin-mediated inhibition of hepatic cholesterol biosynthesis or depletion of hepatic Srebp2 reversed fructose-induced liver injury in Chrebp-KO mice. Mechanistically, we determined that ChREBP binds to nuclear SREBP2 to promote its ubiquitination and destabilization in cultured cells. Therefore, our findings demonstrate that ChREBP provides hepatoprotection against a HFrD by preventing overactivation of cholesterol biosynthesis and the subsequent CHOP-mediated, proapoptotic unfolded protein response. Our findings also identified a role for ChREBP in regulating SREBP2-dependent cholesterol metabolism.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28628040      PMCID: PMC5490767          DOI: 10.1172/JCI89934

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  46 in total

1.  Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease.

Authors:  Jody Dushay; Patricia C Chui; Gosala S Gopalakrishnan; Marta Varela-Rey; Meghan Crawley; Ffolliott M Fisher; Michael K Badman; Maria L Martinez-Chantar; Eleftheria Maratos-Flier
Journal:  Gastroenterology       Date:  2010-05-05       Impact factor: 22.682

2.  The ER stress pathway involving CHOP is activated in the lungs of LPS-treated mice.

Authors:  Motoyoshi Endo; Seiichi Oyadomari; Moritaka Suga; Masataka Mori; Tomomi Gotoh
Journal:  J Biochem       Date:  2005-10       Impact factor: 3.387

3.  Hepatic SREBP-2 and cholesterol biosynthesis are regulated by FoxO3 and Sirt6.

Authors:  Rongya Tao; Xiwen Xiong; Ronald A DePinho; Chu-Xia Deng; X Charlie Dong
Journal:  J Lipid Res       Date:  2013-07-23       Impact factor: 5.922

Review 4.  The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease.

Authors:  Kyoko Nomura; Toshikazu Yamanouchi
Journal:  J Nutr Biochem       Date:  2011-11-29       Impact factor: 6.048

5.  Control of lipid metabolism by phosphorylation-dependent degradation of the SREBP family of transcription factors by SCF(Fbw7).

Authors:  Anders Sundqvist; Maria T Bengoechea-Alonso; Xin Ye; Vasyl Lukiyanchuk; Jianping Jin; J Wade Harper; Johan Ericsson
Journal:  Cell Metab       Date:  2005-06       Impact factor: 27.287

6.  MiR-33 contributes to the regulation of cholesterol homeostasis.

Authors:  Katey J Rayner; Yajaira Suárez; Alberto Dávalos; Saj Parathath; Michael L Fitzgerald; Norimasa Tamehiro; Edward A Fisher; Kathryn J Moore; Carlos Fernández-Hernando
Journal:  Science       Date:  2010-05-13       Impact factor: 47.728

7.  Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob/ob) mice.

Authors:  Katsumi Iizuka; Bonnie Miller; Kosaku Uyeda
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-05-16       Impact factor: 4.310

Review 8.  Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader
Journal:  Prog Lipid Res       Date:  2012-12-01       Impact factor: 16.195

Review 9.  Dietary fructose in nonalcoholic fatty liver disease.

Authors:  Miriam B Vos; Joel E Lavine
Journal:  Hepatology       Date:  2013-05-01       Impact factor: 17.425

10.  Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.

Authors:  Hae-Ki Min; Ashwani Kapoor; Michael Fuchs; Faridoddin Mirshahi; Huiping Zhou; James Maher; John Kellum; Russell Warnick; Melissa J Contos; Arun J Sanyal
Journal:  Cell Metab       Date:  2012-05-02       Impact factor: 27.287

View more
  35 in total

1.  ChREBP refines the hepatic response to fructose to protect the liver from injury.

Authors:  Angela M Hall; Brian N Finck
Journal:  J Clin Invest       Date:  2017-06-19       Impact factor: 14.808

2.  AMPK directly activates mTORC2 to promote cell survival during acute energetic stress.

Authors:  Dubek Kazyken; Brian Magnuson; Cagri Bodur; Hugo A Acosta-Jaquez; Deqiang Zhang; Xin Tong; Tammy M Barnes; Gabrielle K Steinl; Nicole E Patterson; Christopher H Altheim; Naveen Sharma; Ken Inoki; Gregory D Cartee; Dave Bridges; Lei Yin; Steven M Riddle; Diane C Fingar
Journal:  Sci Signal       Date:  2019-06-11       Impact factor: 8.192

Review 3.  Fructose and hepatic insulin resistance.

Authors:  Samir Softic; Kimber L Stanhope; Jeremie Boucher; Senad Divanovic; Miguel A Lanaspa; Richard J Johnson; C Ronald Kahn
Journal:  Crit Rev Clin Lab Sci       Date:  2020-01-14       Impact factor: 6.250

4.  The hepatic BMAL1/AKT/lipogenesis axis protects against alcoholic liver disease in mice via promoting PPARα pathway.

Authors:  Deqiang Zhang; Xin Tong; Bradley B Nelson; Ethan Jin; Julian Sit; Nicholas Charney; Meichan Yang; M Bishr Omary; Lei Yin
Journal:  Hepatology       Date:  2018-05-20       Impact factor: 17.425

5.  Intestinal, but not hepatic, ChREBP is required for fructose tolerance.

Authors:  MiSung Kim; Inna I Astapova; Sarah N Flier; Sarah A Hannou; Ludivine Doridot; Ashot Sargsyan; Henry H Kou; Alan J Fowler; Guosheng Liang; Mark A Herman
Journal:  JCI Insight       Date:  2017-12-21

Review 6.  Curcumin and dietary polyphenol research: beyond drug discovery.

Authors:  Tian-Ru Jin
Journal:  Acta Pharmacol Sin       Date:  2018-03-15       Impact factor: 6.150

7.  Impact of obesity on the toxicity of a multi-ingredient dietary supplement, OxyELITE Pro™ (New Formula), using the novel NZO/HILtJ obese mouse model: Physiological and mechanistic assessments.

Authors:  Charles M Skinner; Isabelle R Miousse; Laura E Ewing; Vijayalakshmi Sridharan; Maohua Cao; Haixia Lin; D Keith Williams; Bharathi Avula; Saqlain Haider; Amar G Chittiboyina; Ikhlas A Khan; Mahmoud A ElSohly; Marjan Boerma; Bill J Gurley; Igor Koturbash
Journal:  Food Chem Toxicol       Date:  2018-09-30       Impact factor: 6.023

8.  MondoA regulates gene expression in cholesterol biosynthesis-associated pathways required for zebrafish epiboly.

Authors:  Meltem Weger; Benjamin D Weger; Andrea Schink; Masanari Takamiya; Johannes Stegmaier; Cédric Gobet; Alice Parisi; Andrei Yu Kobitski; Jonas Mertes; Nils Krone; Uwe Strähle; Gerd Ulrich Nienhaus; Ralf Mikut; Frédéric Gachon; Philipp Gut; Thomas Dickmeis
Journal:  Elife       Date:  2020-09-24       Impact factor: 8.140

Review 9.  Fructose metabolism and metabolic disease.

Authors:  Sarah A Hannou; Danielle E Haslam; Nicola M McKeown; Mark A Herman
Journal:  J Clin Invest       Date:  2018-02-01       Impact factor: 14.808

10.  The Small Intestine Converts Dietary Fructose into Glucose and Organic Acids.

Authors:  Cholsoon Jang; Sheng Hui; Wenyun Lu; Alexis J Cowan; Raphael J Morscher; Gina Lee; Wei Liu; Gregory J Tesz; Morris J Birnbaum; Joshua D Rabinowitz
Journal:  Cell Metab       Date:  2018-02-06       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.